Navigation Links
Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:8/16/2010

RYE, N.Y., Aug. 16 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference, scheduled for September 12-15 at the New York Palace Hotel in New York City.

Dr. Joan Fallon, Curemark's founder and CEO, will update investors on the progress of the company's clinical research for CM-AT, its autism treatment in development.  She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the FDA for CM – 4612 to treat attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

"We are very happy to have this opportunity to present at the Rodman & Renshaw annual investment conference.  Curemark has achieved a variety of major milestones that we are looking forward to sharing with attendees," Fallon said.  

CM-AT, Curemark's autism treatment, addresses enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  Phase III clinical trials are underway at 13 sites nationwide for CM-AT, which has received Fast Track status from the FDA.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          

Curemark's presentation is part of the 12th annual healthcare conference, an industry track that will be showcased during the Rodman & Renshaw Annual Global Investment Conference.  In addition to healthcare, the conference will highlight industry tracks including China, metals and mining, energy, technology, cleantech, community and regional banks, and REITs.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Opens Autism Trials at New Jersey Site
2. Curemark Begins Autism Trials at Two More Sites
3. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
4. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
5. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
9. Curemark Announces Senior Executive Promotions
10. Curemark CEO Presents at Epigenomics Conference
11. Curemark Closes Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... research report titled Chronic Inflammation Global Clinical Trials ... snapshot of the global clinical trials landscape along ... trials by Region, Country (G7 & E7), Trial ... status and reviews top companies involved and enlists ...
(Date:2/11/2016)... Laboratory glassware and plasticware include ... may range from microscope slides to large storage boxes ... borosilicate glass because of its low weight and resistance ... started gaining popularity over the past decade when it ... with plastic in several applications due to its resistance ...
Breaking Medicine Technology:
(Date:2/14/2016)... ... February 14, 2016 , ... Many eating ... professionals near their residence. The nature of the illnesses requires ongoing supervision, therapy ... time allotted at work to make traditional appointments. These people struggle to maintain ...
(Date:2/13/2016)... ... February 13, 2016 , ... Good news for retinal patients ... area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging technology used to ... diabetic retinopathy, and other vascular conditions. , In just a few seconds, OCT ...
(Date:2/13/2016)... Angeles, California (PRWEB) , ... February 13, 2016 , ... ... help landing a date for the big day. A great outfit, flawless hair, and ... ashtray, they might as well resign themselves to a night at home with Rover. ...
(Date:2/13/2016)... ... ... individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased their ... delved into this niche allowing those giving up their beloved pasta a chance to ... of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio that ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
Breaking Medicine News(10 mins):